

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For other titles published in this series, go to
www.springer.com/series/7651

METHODS IN MOLECULAR BIOLOGY™

Therapeutic Applications of RNAi

Methods and Protocols

Edited by

John F. Reidhaar-Olson

Cristina M. Rondinone

Hoffmann-La Roche Inc., Nutley, NJ, USA

 **Humana Press**

Editors

John F. Reidhaar-Olson
Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley NJ 07110
USA
john.reidhaar-olson@roche.com

Cristina M. Rondinone
Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley NJ 07110
USA
cristina.rondinone@roche.com

ISSN 1064-3745 e-ISSN 1940-6029
ISBN 978-1-60327-294-0 e-ISBN 978-1-60327-295-7
DOI 10.1007/978-1-60327-295-7
Springer Dordrecht Heidelberg London New York

Library of Congress Control Number: 2009926661

© Humana Press, a part of Springer Science+Business Media, LLC 2009

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

In the short time since its discovery, RNA interference (RNAi) has become a well-established tool in the drug discovery process. The ability to knock down expression of any gene in mammalian cells using a straightforward method has revolutionized the processes of target identification and validation, and helped to usher in the era of functional genomics. RNAi is a process in which cytoplasmic long double-stranded RNAs (dsRNAs) produced by viral infection, transposons, or introduced transgenes are targeted for inactivation. These long dsRNAs are processed into 21- to 23-nucleotide RNA duplexes by an RNase called Dicer, and are further incorporated into an RNA-induced silencing complex (RISC). The RISC uses these small RNAs to identify and cleave homologous mRNAs in the cell.

RNAi has been used to interrogate the function of candidate genes and, more recently, following the creation of random and directed siRNA libraries, has permitted phenotype-driven, reverse genetic analysis of normal physiological and disease processes. The development of stable and inducible expression vectors driving the expression of short hairpin RNAs has further expanded the application of RNAi both in tissue culture and in animal models.

Beyond its utility as a research tool, the use of RNAi as a therapeutic method promises to bring about an even greater revolution in drug discovery. The key features of RNAi – its high degree of specificity, the ubiquity of its mechanism in all cell types, its catalytic nature, and its ability to target virtually any gene in the genome – have generated excitement that RNAi-based drugs may soon become a reality. While the field of RNAi-based therapeutics is still in its early stages, research is moving ahead rapidly, with several siRNAs already being tested in the clinic.

However, significant hurdles remain, with drug delivery key among them. Delivering siRNA molecules to the right tissue and cell type to treat disease is difficult. Getting siRNAs across the cell membrane and into the cytoplasm where they can effectively silence their targets poses significant challenges. And formulating RNAi-based drugs in ways that allow convenient administration is a difficult problem as well. Currently, many delivery methods are being explored, and many have shown promising results in preclinical models. In some cases, local delivery of an unmodified siRNA may be possible with nothing more than a simple excipient as formulation. But in most cases, some sort of delivery vehicle is required. Many classes of delivery agents are under investigation, including liposomes and lipoplexes, conjugates, polymers and nanoparticles, peptides and proteins. In all of these cases, the challenge is to couple effective delivery with acceptable safety.

With few RNAi programs yet in the clinic, most of the focus remains at earlier stages: testing of delivery vehicles, identifying appropriate model systems, and evaluating the effects of RNAi *in vivo*. The chapters in this volume address these aspects of research toward the therapeutic application of RNAi. They describe the therapeutic applications of RNAi and potential pitfalls in oncology, viral infections, and CNS disease, using a variety of delivery methods, including liposomes, peptide-based nanoparticles, polycationic polymers, and viral vehicles. In all cases, detailed protocols are provided, to allow

application of these techniques in the reader's laboratory. The collection of essays, by a team of internationally renowned authors, includes basic science chapters dealing with the biology and design of RNAi, essays describing novel strategies for delivery in vivo, and papers that discuss the application of RNAi in a variety of therapeutic areas. This volume will be of interest to basic and clinical researchers, biochemists, clinicians, molecular biologists, physiologists, and pharmacologists.

John F. Reidhaar-Olson
Cristina M. Rondinone

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>
1 Development and Application of a Dual-Purpose Nanoparticle Platform for Delivery and Imaging of siRNA in Tumors	1
<i>Zdravka Medarova, Mohanraja Kumar, Shu-wing Ng, and Anna Moore</i>	
2 Targeted Gene Silencing into Solid Tumors with Electrically Mediated siRNA Delivery	15
<i>Muriel Golzio, Laurent Mazzolini, Aurélie Paganin-Gioanni, and Justin Teissié</i>	
3 Liposomal siRNA for Ovarian Cancer	29
<i>Lingegowda S. Mangala, Hee Dong Han, Gabriel Lopez-Berestein, and Anil K. Sood</i>	
4 Therapeutic Applications of RNAi for Silencing Virus Replication	43
<i>Ralph A. Tripp and Stephen Mark Tompkins</i>	
5 RNAi in the Malaria Vector, <i>Anopheles gambiae</i>	63
<i>Flaminia Catteruccia and Elena A. Levashina</i>	
6 RNAi Using a Chitosan/siRNA Nanoparticle System: In Vitro and In Vivo Applications	77
<i>Morten Østergaard Andersen, Kenneth Alan Howard, and Jørgen Kjems</i>	
7 Lentiviral and Adeno-Associated Vector-Based Therapy for Motor Neuron Disease Through RNAi	87
<i>Chris Towne and Patrick Aebischer</i>	
8 Studying Autoimmunity by In Vivo RNA Interference	109
<i>Stephan Kissler</i>	
9 Transcriptional Gene Silencing Using Small RNAs	119
<i>Daniel H. Kim and John J. Rossi</i>	
10 Alternative Splicing as a Therapeutic Target for Human Diseases	127
<i>Kenneth J. Dery, Veronica Gusti, Shikha Gaur, John E. Shively, Yun Yen, and Rajesh K. Gaur</i>	
<i>Index</i>	145

Contributors

- PATRICK AEBISCHER • *Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland*
- MORTEN ØSTERGAARD ANDERSEN • *Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology, University of Aarhus, Aarhus C, Denmark*
- FLAMINIA CATTERUCCIA • *Division of Cell and Molecular Biology, Faculty of Life Sciences, Imperial College London, London, UK*
- KENNETH J. DERY • *Divisions of Molecular Biology and Immunology, Beckman Research Institute of the City of Hope, Duarte, CA, USA*
- RAJESH K. GAUR • *Division of Molecular Biology and Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA*
- SHIKHA GAUR • *Department of Clinical and Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA, USA*
- MURIEL GOLZIO • *IPBS Université P Sabatier and CNRS (UMR 5089), Toulouse, France*
- VERONICA GUSTI • *Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA*
- HEE DONG HAN • *Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- KENNETH ALAN HOWARD • *Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology, University of Aarhus, Aarhus C, Denmark*
- DANIEL H. KIM • *Howard Hughes Medical Institute, Department of Molecular Biology, Massachusetts General Hospital and Department of Genetics, Harvard Medical School, Boston, MA, USA*
- STEPHAN KISSLER • *Rudolf Virchow Center / DFG Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany*
- JØRGEN KJEMS • *Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology, University of Aarhus, Aarhus C, Denmark*
- MOHANRAJA KUMAR • *Molecular Imaging Program, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA*
- ELENA A. LEVASHINA • *UPR9022 du CNRS, Group AVENIR Inserm, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France*
- GABRIEL LOPEZ-BERESTEIN • *Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- LINGEGOWDA S. MANGALA • *Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- LAURENT MAZZOLINI • *CRPS CNRS- Pierre Fabre (UMR 2587), Toulouse, France*
- ZDRAVKA MEDAROVA • *Molecular Imaging Program, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA*

- ANNA MOORE • *Molecular Imaging Program, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA*
- SHU-WING NG • *Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA*
- AURÉLIE PAGANIN-GIOANNI • *IPBS Université P Sabatier and CNRS (UMR 5089), Toulouse, France*
- JOHN F. REIDHAAR-OLSON • *RNA Therapeutics, Hoffmann-La Roche, Inc., Nutley, NJ, USA*
- CRISTINA M. RONDINONE • *Metabolic and Vascular Diseases, Hoffmann-La Roche, Inc., Nutley, NJ, USA*
- JOHN J. ROSSI • *Graduate School of Biological Sciences and Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA*
- JOHN E. SHIVELY • *Division of Immunology, Beckman Research Institute of the City of Hope Duarte, CA, USA*
- ANIL K. SOOD • *Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- JUSTIN TEISSIÉ • *IPBS Université P Sabatier and CNRS (UMR 5089), Toulouse, France*
- STEPHEN MARK TOMPKINS • *Department of Infectious Diseases, College of Veterinary Medicine Center for Disease Intervention, University of Georgia, Athens, GA, USA*
- CHRIS TOWNE • *Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland*
- RALPH A. TRIPP • *Department of Infectious Diseases, College of Veterinary Medicine, Center for Disease Intervention, University of Georgia, Athens, GA, USA*
- YUN YEN • *Department of Clinical and Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA, USA*